Download PDF
Semin Thromb Hemost 2019; 45(04): 326-333
DOI: 10.1055/s-0039-1687892
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Thrombotic Complications in Gliomas

Alexandra L. Czap
1   Department of Neurology, University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas
,
Ashley Becker
1   Department of Neurology, University of Texas Health Science Center at Houston McGovern Medical School, Houston, Texas
,
Patrick Y. Wen
2   Center for Neuro-Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts
› Author Affiliations
Further Information

Publication History

Publication Date:
30 April 2019 (online)

    Permissions and Reprints

Abstract

Arterial and venous thromboses are common in glioma patients, both in the perioperative period and throughout the course of the disease. High-grade glioma patients harbor underlying hypercoagulability, which predisposes these high-risk patients with prolonged immobility and neurologic deficits to thrombotic events. Despite the high incidence and recurrent nature of these complications, there is no standardized approach to the management of glioma patients, and many challenges remain. Historically, the perceived risk of intracranial and intratumoral hemorrhage limited the use of anticoagulation, favoring nonpharmacological prophylaxis and treatment. Multiple studies have demonstrated the safety and efficacy of anticoagulation when indicated, with low molecular weight heparin as the preferred short- or long-term treatment. This review will discuss the epidemiology, risk factors, and therapeutic management of both venous and arterial thrombotic complications in glioma.

Keywords

glioma - thromboembolism - deep venous thrombosis - pulmonary embolism - ischemic stroke
 

  • References

  • 1 Timp JF, Braekkan SK, Versteeg HH, Cannegieter SC. Epidemiology of cancer-associated venous thrombosis. Blood 2013; 122 (10) 1712-1723
    PubMedGoogle Scholar
  • 2 Mandel JJ, Yust-Katz S, Wu J. , et al. Venous thromboembolism (VTE) and glioblastoma. J Clin Oncol 2014; 32: 5s
    PubMedGoogle Scholar
  • 3 Edwin NC, Elson P, Ahluwalia MS, Khorana AA. Venous thromboembolism in patients with glioblastoma: risk factors and prognostic importance. J Clin Oncol 2015; 33 (15 Suppl): e13027
    CrossrefPubMedGoogle Scholar
  • 4 Marras LC, Geerts WH, Perry JR. The risk of venous thromboembolism is increased throughout the course of malignant glioma: an evidence-based review. Cancer 2000; 89 (03) 640-646
    CrossrefPubMedGoogle Scholar
  • 5 Perry JR, Julian JA, Laperriere NJ. , et al. PRODIGE: a randomized placebo-controlled trial of dalteparin low-molecular-weight heparin thromboprophylaxis in patients with newly diagnosed malignant glioma. J Thromb Haemost 2010; 8 (09) 1959-1965
    CrossrefPubMedGoogle Scholar
  • 6 Chaichana KL, Pendleton C, Jackson C. , et al. Deep venous thrombosis and pulmonary embolisms in adult patients undergoing craniotomy for brain tumors. Neurol Res 2013; 35 (02) 206-211
    CrossrefPubMedGoogle Scholar
  • 7 Sawaya R, Zuccarello M, Elkalliny M, Nishiyama H. Postoperative venous thromboembolism and brain tumors: part I. Clinical profile. J Neurooncol 1992; 14 (02) 119-125
    PubMedGoogle Scholar
  • 8 Anderson F, Huang W, Sullivan C. , et al. The continuing risk of venous thromboembolism following operation for glioma: findings from the Glioma Outcomes Project. Thromb Haemost 2001; 86 (Suppl): OC902 [Abstract]
    Article in Thieme ConnectPubMedGoogle Scholar
  • 9 Brandes AA, Scelzi E, Salmistraro G. , et al. Incidence of risk of thromboembolism during treatment high-grade gliomas: a prospective study. Eur J Cancer 1997; 33 (10) 1592-1596
    CrossrefPubMedGoogle Scholar
  • 10 Dickinson H, Carico C, Nuño M. , et al. Unplanned readmissions and survival following brain tumor surgery. J Neurosurg 2015; 122 (01) 61-68
    CrossrefPubMedGoogle Scholar
  • 11 Schiff D, Lee EQ, Nayak L, Norden AD, Reardon DA, Wen PY. Medical management of brain tumors and the sequelae of treatment. Neuro-oncol 2015; 17 (04) 488-504
    PubMedGoogle Scholar
  • 12 Khorana AA, Connolly GC. Assessing risk of venous thromboembolism in the patient with cancer. J Clin Oncol 2009; 27 (29) 4839-4847
    CrossrefPubMedGoogle Scholar
  • 13 Khorana AA. Risk assessment for cancer-associated thrombosis: what is the best approach?. Thromb Res 2012; 129 (Suppl. 01) S10-S15
    CrossrefPubMedGoogle Scholar
  • 14 Cheruku R, Tapazoglou E, Ensley J, Kish JA, Cummings GD, al-Sarraf M. The incidence and significance of thromboembolic complications in patients with high-grade gliomas. Cancer 1991; 68 (12) 2621-2624
    CrossrefPubMedGoogle Scholar
  • 15 Streiff MB, Segal J, Grossman SA, Kickler TS, Weir EG. ABO blood group is a potent risk factor for venous thromboembolism in patients with malignant gliomas. Cancer 2004; 100 (08) 1717-1723
    CrossrefPubMedGoogle Scholar
  • 16 Rodas RA, Fenstermaker RA, McKeever PE. , et al. Correlation of intraluminal thrombosis in brain tumor vessels with postoperative thrombotic complications: a preliminary report. J Neurosurg 1998; 89 (02) 200-205
    CrossrefPubMedGoogle Scholar
  • 17 Prayson NF, Angelov L, Prayson RA. Microscopic thrombi in glioblastoma multiforme do not predict the development of deep venous thrombosis. Ann Diagn Pathol 2009; 13 (05) 291-296
    CrossrefPubMedGoogle Scholar
  • 18 Ruff RL, Posner JB. Incidence and treatment of peripheral venous thrombosis in patients with glioma. Ann Neurol 1983; 13 (03) 334-336
    CrossrefPubMedGoogle Scholar
  • 19 Gerber DE, Grossman SA, Streiff MB. Management of venous thromboembolism in patients with primary and metastatic brain tumors. J Clin Oncol 2006; 24 (08) 1310-1318
    CrossrefPubMedGoogle Scholar
  • 20 Simanek R, Vormittag R, Hassler M. , et al. Venous thromboembolism and survival in patients with high-grade glioma. Neuro-oncol 2007; 9 (02) 89-95
    CrossrefPubMedGoogle Scholar
  • 21 Rong Y, Belozerov VE, Tucker-Burden C. , et al. Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res 2009; 69 (06) 2540-2549
    CrossrefPubMedGoogle Scholar
  • 22 Jo JT, Schiff D, Perry JR. Thrombosis in brain tumors. Semin Thromb Hemost 2014; 40 (03) 325-331
    Article in Thieme ConnectPubMedGoogle Scholar
  • 23 Zangari M, Fink LM, Elice F, Zhan F, Adcock DM, Tricot GJ. Thrombotic events in patients with cancer receiving antiangiogenesis agents. J Clin Oncol 2009; 27 (29) 4865-4873
    CrossrefPubMedGoogle Scholar
  • 24 Misch M, Czabanka M, Dengler J. , et al. D-dimer elevation and paresis predict thromboembolic events during bevacizumab therapy for recurrent malignant glioma. Anticancer Res 2013; 33 (05) 2093-2098
    PubMedGoogle Scholar
  • 25 Thaler J, Ay C, Kaider A. , et al. Biomarkers predictive of venous thromboembolism in patients with newly diagnosed high-grade gliomas. Neuro-oncol 2014; 16 (12) 1645-1651
    PubMedGoogle Scholar
  • 26 Pabinger I, Thaler J, Ay C. Biomarkers for prediction of venous thromboembolism in cancer. Blood 2013; 122 (12) 2011-2018
    PubMedGoogle Scholar
  • 27 Khorana AA, Kuderer NM, Culakova E, Lyman GH, Francis CW. Development and validation of a predictive model for chemotherapy-associated thrombosis. Blood 2008; 111 (10) 4902-4907
    CrossrefPubMedGoogle Scholar
  • 28 Trujillo-Santos J, Di Micco P, Iannuzzo M. , et al; RIETE Investigators. Elevated white blood cell count and outcome in cancer patients with venous thromboembolism. Findings from the RIETE Registry. Thromb Haemost 2008; 100 (05) 905-911
    Article in Thieme ConnectPubMedGoogle Scholar
  • 29 Ay C, Vormittag R, Dunkler D. , et al. D-dimer and prothrombin fragment 1 + 2 predict venous thromboembolism in patients with cancer: results from the Vienna Cancer and Thrombosis Study. J Clin Oncol 2009; 27 (25) 4124-4129
    CrossrefPubMedGoogle Scholar
  • 30 Vormittag R, Simanek R, Ay C. , et al. High factor VIII levels independently predict venous thromboembolism in cancer patients: the cancer and thrombosis study. Arterioscler Thromb Vasc Biol 2009; 29 (12) 2176-2181
    CrossrefPubMedGoogle Scholar
  • 31 Zou JP, Morford LA, Chougnet C. , et al. Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers. J Immunol 1999; 162 (08) 4882-4892
    PubMedGoogle Scholar
  • 32 Jenkins EO, Schiff D, Mackman N, Key NS. Venous thromboembolism in malignant gliomas. J Thromb Haemost 2010; 8 (02) 221-227
    PubMedGoogle Scholar
  • 33 Kocatürk B, Versteeg HH. Tissue factor isoforms in cancer and coagulation: may the best isoform win. Thromb Res 2012; 129 (Suppl. 01) S69-S75
    CrossrefPubMedGoogle Scholar
  • 34 Garnier D, Magnus N, D'Asti E. , et al. Genetic pathways linking hemostasis and cancer. Thromb Res 2012; 129 (Suppl. 01) S22-S29
    CrossrefPubMedGoogle Scholar
  • 35 Tehrani M, Friedman TM, Olson JJ, Brat DJ. Intravascular thrombosis in central nervous system malignancies: a potential role in astrocytoma progression to glioblastoma. Brain Pathol 2008; 18 (02) 164-171
    PubMedGoogle Scholar
  • 36 Rong Y, Post DE, Pieper RO, Durden DL, Van Meir EG, Brat DJ. PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res 2005; 65 (04) 1406-1413
    CrossrefPubMedGoogle Scholar
  • 37 Blum S, Issbruker K, Willuweit A. , et al. An inhibitory role of the phosphatidylinositol 3-kinase-signaling pathway in vascular endothelial growth factor-induced tissue factor expression. J Biol Chem 2001; 276: 33428-33434
    CrossrefPubMedGoogle Scholar
  • 38 Sartori MT, Della Puppa A, Ballin A. , et al. Prothrombotic state in glioblastoma multiforme: an evaluation of the procoagulant activity of circulating microparticles. J Neurooncol 2011; 104 (01) 225-231
    CrossrefPubMedGoogle Scholar
  • 39 Lyman GH, Bohlke K, Falanga A. ; American Society of Clinical Oncology. Venous thromboembolism prophylaxis and treatment in patients with cancer: American Society of Clinical Oncology clinical practice guideline update. J Oncol Pract 2015; 11 (03) e442-e444
    CrossrefPubMedGoogle Scholar
  • 40 Farge D, Debourdeau P, Beckers M. , et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11 (01) 56-70
    CrossrefPubMedGoogle Scholar
  • 41 Agnelli G, Piovella F, Buoncristiani P. , et al. Enoxaparin plus compression stockings compared with compression stockings alone in the prevention of venous thromboembolism after elective neurosurgery. N Engl J Med 1998; 339: 80-85
    CrossrefPubMedGoogle Scholar
  • 42 Frisius J, Ebeling M, Karst M. , et al. Prevention of venous thromboembolic complications with and without intermittent pneumatic compression in neurosurgical cranial procedures using intraoperative magnetic resonance imaging. A retrospective analysis. Clin Neurol Neurosurg 2015; 133: 46-54
    CrossrefPubMedGoogle Scholar
  • 43 Lukassen JNM, Groen JL, Jacobs WC, Vleggeert-Lankamp CLA. Thromboembolic prophylaxis in neurosurgical practice: a review. J Spine 2014; 4: 1-7
    PubMedGoogle Scholar
  • 44 Constantini S, Kanner A, Friedman A. , et al. Safety of perioperative minidose heparin in patients undergoing brain tumor surgery: a prospective, randomized, double-blind study. J Neurosurg 2001; 94 (06) 918-921
    CrossrefPubMedGoogle Scholar
  • 45 Iorio A, Agnelli G. Low-molecular-weight and unfractionated heparin for prevention of venous thromboembolism in neurosurgery: a meta-analysis. Arch Intern Med 2000; 160 (15) 2327-2332
    CrossrefPubMedGoogle Scholar
  • 46 Geerts WH, Bergqvist D, Pineo GF. , et al. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guideline (8th Edition). Chest 2008; 133 (6 Suppl): 381S-453S
    CrossrefPubMedGoogle Scholar
  • 47 Dickinson LD, Miller LD, Patel CP. , et al. Enoxaparin increases the incidence of postoperative intracranial hemorrhage when initiated preoperatively for deep venous thrombosis prophylaxis in patients with brain tumors. Neurosurgery 1998; 43: 1074-1081
    CrossrefPubMedGoogle Scholar
  • 48 Perry JR. Thromboembolic disease in patients with high-grade glioma. Neuro-oncol 2012; 14 (Suppl. 04) iv73-iv80
    PubMedGoogle Scholar
  • 49 Sørensen HT, Mellemkjaer L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343 (25) 1846-1850
    CrossrefPubMedGoogle Scholar
  • 50 van Leeuwen RW, Jansman FG, van den Bemt PM. , et al. Drug-drug interactions in patients treated for cancer: a prospective study on clinical interventions. Ann Oncol 2015; 26 (05) 992-997
    CrossrefPubMedGoogle Scholar
  • 51 Lieu AS, Hwang SL, Howng SL, Chai CY. Brain tumors with hemorrhage. J Formos Med Assoc 1999; 98 (05) 365-367
    PubMedGoogle Scholar
  • 52 Bitoh S, Hasegawa H, Ohtsuki H, Obashi J, Fujiwara M, Sakurai M. Cerebral neoplasms initially presenting with massive intracerebral hemorrhage. Surg Neurol 1984; 22 (01) 57-62
    CrossrefPubMedGoogle Scholar
  • 53 Kearon C, Akl EA, Comerota AJ. , et al. Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 142 (06) 1698-1704
    PubMedGoogle Scholar
  • 54 Mandalà M, Falanga A, Roila F. ; ESMO Guidelines Working Group. Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines. Ann Oncol 2011; 22 (Suppl. 06) vi85-vi92
    CrossrefPubMedGoogle Scholar
  • 55 Lee AY, Levine MN, Baker RI. , et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 2003; 349 (02) 146-153
    CrossrefPubMedGoogle Scholar
  • 56 Louzada ML, Majeed H, Wells PS. Efficacy of low- molecular- weight- heparin versus vitamin K antagonists for long term treatment of cancer-associated venous thromboembolism in adults: a systematic review of randomized controlled trials. Thromb Res 2009; 123 (06) 837-844
    CrossrefPubMedGoogle Scholar
  • 57 Lee AY. Treatment of established thrombotic events in patients with cancer. Thromb Res 2012; 129 (Suppl. 01) S146-S153
    CrossrefPubMedGoogle Scholar
  • 58 Lee AYY, Kamphuisen PW, Meyer G. , et al; CATCH Investigators. Tinzaparin vs warfarin for treatment of acute venous thromboembolism in patients with active cancer: a randomized controlled clinical trial. JAMA 2015; 314 (07) 677-686
    CrossrefPubMedGoogle Scholar
  • 59 Mantia C, Uhlmann EJ, Puligandla M, Weber GM, Neuberg D, Zwicker JI. Predicting the higher rate of intracranial hemorrhage in glioma patients receiving therapeutic enoxaparin. Blood 2017; 129 (25) 3379-3385
    CrossrefPubMedGoogle Scholar
  • 60 Verso M, Agnelli G. New and old anticoagulants in cancer. Thromb Res 2012; 129 (Suppl. 01) S101-S105
    CrossrefPubMedGoogle Scholar
  • 61 Carney BJ, Uhlmann EJ, Puligandla M. , et al. Intracranial hemorrhage with direct oral anticoagulants in patients with brain tumors. J Thromb Haemost 2019; 17 (01) 72-76
    CrossrefPubMedGoogle Scholar
  • 62 Raskob GE, van Es N, Verhamme P. , et al; Hokusai VTE Cancer Investigators. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med 2018; 378 (07) 615-624
    CrossrefPubMedGoogle Scholar
  • 63 Young AM, Marshall A, Thirlwall J. , et al. Comparison of an oral factor Xa inhibitor with low molecular weight heparin in patients with cancer with venous thromboembolism: results of a randomized trial (SELECT-D). J Clin Oncol 2018; 36 (20) 2017-2023
    CrossrefPubMedGoogle Scholar
  • 64 ClinicalTrials.gov. Direct Oral Anticoagulants (DOACs) Versus LMWH +/- Warfarin for VTE in Cancer (CANVAS). https://clinicaltrials.gov/ct2/show/NCT02744092 . Accessed September 15, 2018
    PubMedGoogle Scholar
  • 65 Levin JM, Schiff D, Loeffler JS. , et al. Complications of therapy for venous thromboembolic disease in patients with brain tumors. Neurology 1993; 43: 1111-1114
    CrossrefPubMedGoogle Scholar
  • 66 Schiff D, DeAngelis LM. Therapy of venous thromboembolism in patients with brain metastases. Cancer 1994; 73 (02) 493-498
    CrossrefPubMedGoogle Scholar
  • 67 Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305 (05) 487-494
    CrossrefPubMedGoogle Scholar
  • 68 Chinot OL, Wick W, Mason W. , et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (08) 709-722
    CrossrefPubMedGoogle Scholar
  • 69 Gilbert MR, Dignam JJ, Armstrong TS. , et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med 2014; 370 (08) 699-708
    CrossrefPubMedGoogle Scholar
  • 70 Simonetti G, Trevisan E, Silvani A. , et al. Safety of bevacizumab in patients with malignant gliomas: a systematic review. Neurol Sci 2014; 35 (01) 83-89
    PubMedGoogle Scholar
  • 71 Khasraw M, Ameratunga M, Grommes C. Bevacizumab for the treatment of high-grade glioma: an update after phase III trials. Expert Opin Biol Ther 2014; 14 (05) 729-740
    CrossrefPubMedGoogle Scholar
  • 72 Norden AD, Bartolomeo J, Tanaka S. , et al. Safety of concurrent bevacizumab therapy and anticoagulation in glioma patients. J Neurooncol 2012; 106 (01) 121-125
    CrossrefPubMedGoogle Scholar
  • 73 Robins HI, O'Neill A, Gilbert M. , et al. Effect of dalteparin and radiation on survival and thromboembolic events in glioblastoma multiforme: a phase II ECOG trial. Cancer Chemother Pharmacol 2008; 62 (02) 227-233
    CrossrefPubMedGoogle Scholar
  • 74 Perry SL, Bohlin C, Reardon DA. , et al. Tinzaparin prophylaxis against venous thromboembolic complications in brain tumor patients. J Neurooncol 2009; 95 (01) 129-134
    CrossrefPubMedGoogle Scholar
  • 75 Kuhn SA, Marosi C, Pabinger I. , et al. CoaGlio IV trial: randomized, controlled, triple-blind, multinational phase III study of adjuvant prophylactic anticoagulation in patients with glioblastoma WHO IV. J Clin Oncol 2015; 33: 15
    PubMedGoogle Scholar
  • 76 Cestari DM, Weine DM, Panageas KS, Segal AZ, DeAngelis LM. Stroke in patients with cancer: incidence and etiology. Neurology 2004; 62 (11) 2025-2030
    CrossrefPubMedGoogle Scholar
  • 77 Kreisl TN, Toothaker T, Karimi S, DeAngelis LM. Ischemic stroke in patients with primary brain tumors. Neurology 2008; 70 (24) 2314-2320
    CrossrefPubMedGoogle Scholar
  • 78 Bick RL. Cancer-associated thrombosis. N Engl J Med 2003; 349 (02) 109-111
    CrossrefPubMedGoogle Scholar
  • 79 Seidel C, Hentschel B, Simol M. , et al. A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. J Neurol 2013; 260 (03) 847-855
    CrossrefPubMedGoogle Scholar
  • 80 Kamiya-Matsuoka C, Cachia D. . Yust-Katz, et al. Ischemic stroke in patients with gliomas at the University of Texas-M.D. Anderson Cancer Center. J Neuroonc 2015; 125: 143-148
    PubMedGoogle Scholar
  • 81 Obeid M, Ulane C, Rosenfeld S. Pearls & Oy-sters: large vessel ischemic stroke secondary to glioblastoma multiforme. Neurology 2010; 74 (13) e50-e51
    CrossrefPubMedGoogle Scholar
  • 82 Bang OY, Seok JM, Kim SG. , et al. Ischemic stroke and cancer: stroke severely impacts cancer patients, while cancer increases the number of strokes. J Clin Neurol 2011; 7 (02) 53-59
    CrossrefPubMedGoogle Scholar
  • 83 Le Rhun E, Perry JR. Vascular complications in glioma patients. Handb Clin Neurol 2016; 134: 251-266
    PubMedGoogle Scholar
  • 84 Nguyen T, DeAngelis LM. Stroke in cancer patients. Curr Neurol Neurosci Rep 2006; 6 (03) 187-192
    CrossrefPubMedGoogle Scholar
  • 85 Fraum TJ, Kreisl TN, Sul J, Fine HA, Iwamoto FM. Ischemic stroke and intracranial hemorrhage in glioma patients on antiangiogenic therapy. J Neurooncol 2011; 105 (02) 281-289
    CrossrefPubMedGoogle Scholar
  • 86 Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002; 4 (06) 465-473
    CrossrefPubMedGoogle Scholar
  • 87 Falanga A, Gordon SG. Isolation and characterization of cancer procoagulant: a cysteine proteinase from malignant tissue. Biochemistry 1985; 24 (20) 5558-5567
    CrossrefPubMedGoogle Scholar
  • 88 Jander S, Sitzer M, Wendt A. , et al. Expression of tissue factor in high-grade carotid artery stenosis: association with plaque destabilization. Stroke 2001; 32 (04) 850-854
    CrossrefPubMedGoogle Scholar
  • 89 Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand 2009; 119 (01) 1-16
    PubMedGoogle Scholar
  • 90 Navi BB, Reiner AS, Kamel H. , et al. Association between incident cancer and subsequent stroke. Ann Neurol 2015; 77 (02) 291-300
    CrossrefPubMedGoogle Scholar
  • 91 Overell JR, Bone I, Lees KR. Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology 2000; 55 (08) 1172-1179
    CrossrefPubMedGoogle Scholar
  • 92 Kent DM, Thaler DE. Is patent foramen ovale a modifiable risk factor for stroke recurrence?. Stroke 2010; 41 (10, Suppl): S26-S30
    CrossrefPubMedGoogle Scholar
  • 93 el-Shami K, Griffiths E, Streiff M. Nonbacterial thrombotic endocarditis in cancer patients: pathogenesis, diagnosis, and treatment. Oncologist 2007; 12 (05) 518-523
    CrossrefPubMedGoogle Scholar
  • 94 Kooiker JC, MacLean JM, Sumi SM. Cerebral embolism, marantic endocarditis, and cancer. Arch Neurol 1976; 33 (04) 260-264
    CrossrefPubMedGoogle Scholar
  • 95 Seidel C, Hentschel B, Simon M. , et al. A comprehensive analysis of vascular complications in 3,889 glioma patients from the German Glioma Network. J Neurol 2013; 260 (03) 847-855
    CrossrefPubMedGoogle Scholar
  • 96 Little MP, Azizova TV, Bazyka D. , et al. Systematic review and meta-analysis of circulatory disease from exposure to low-level ionizing radiation and estimates of potential population mortality risks. Environ Health Perspect 2012; 120 (11) 1503-1511
    CrossrefPubMedGoogle Scholar
  • 97 Plummer C, Henderson RD, O'Sullivan JD, Read SJ. Ischemic stroke and transient ischemic attack after head and neck radiotherapy: a review. Stroke 2011; 42 (09) 2410-2418
    CrossrefPubMedGoogle Scholar
  • 98 Parikh NS, Burch JE, Kamel H, DeAngelis LM, Navi BB. Recurrent thromboembolic events after ischemic stroke in patients with primary brain tumors. J Stroke Cerebrovasc Dis 2017; 26 (10) 2396-2403
    CrossrefPubMedGoogle Scholar
  • 99 Fullerton HJ, Stratton K, Mueller S. , et al. Recurrent stroke in childhood cancer survivors. Neurology 2015; 85 (12) 1056-1064
    CrossrefPubMedGoogle Scholar
  • 100 Lasocki A, Gaillard F. Ischaemic stroke in the setting of glioblastoma: a case series and review of the literature. Neuroradiol J 2016; 29 (03) 155-159
    CrossrefPubMedGoogle Scholar
  • 101 El-Fayech C, Haddy N, Allodji RS. , et al. Cerebrovascular diseases in childhood cancer survivors: role of the radiation dose to Willis circle arteries. Int J Radiat Oncol Biol Phys 2017; 97 (02) 278-286
    CrossrefPubMedGoogle Scholar
  • 102 Campen CJ, Kranick SM, Kasner SE. , et al. Cranial irradiation increases risk of stroke in pediatric brain tumor survivors. Stroke 2012; 43 (11) 3035-3040
    CrossrefPubMedGoogle Scholar
  • 103 De Bruin ML, Dorresteijn LD, van't Veer MB. , et al. Increased risk of stroke and transient ischemic attack in 5-year survivors of Hodgkin lymphoma. J Natl Cancer Inst 2009; 101 (13) 928-937
    CrossrefPubMedGoogle Scholar
  • 104 Norden AD, Drappatz J, Wen PY. Antiangiogenic therapies for high-grade glioma. Nat Rev Neurol 2009; 5 (11) 610-620
    PubMedGoogle Scholar
  • 105 Auer TA, Renovanz M, Marini F, Brockmann MA, Tanyildizi Y. Ischemic stroke and intracranial hemorrhage in patients with recurrent glioblastoma multiforme, treated with bevacizumab. J Neurooncol 2017; 133 (03) 571-579
    CrossrefPubMedGoogle Scholar
  • 106 Saran F, Chinot OL, Henriksson R. , et al. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro-oncol 2016; 18 (07) 991-1001
    PubMedGoogle Scholar
  • 107 Kuenen BC. Analysis of prothrombotic mechanisms and endothelial perturbation during treatment with angiogenesis inhibitors. Pathophysiol Haemost Thromb 2003; 33 (Suppl. 01) 13-14
    CrossrefPubMedGoogle Scholar
  • 108 Zachary I. Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor. Am J Physiol Cell Physiol 2001; 280 (06) C1375-C1386
    CrossrefPubMedGoogle Scholar
  • 109 Tam BY, Wei K, Rudge JS. , et al. VEGF modulates erythropoiesis through regulation of adult hepatic erythropoietin synthesis. Nat Med 2006; 12 (07) 793-800
    CrossrefPubMedGoogle Scholar
  • 110 Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007; 96 (12) 1788-1795
    CrossrefPubMedGoogle Scholar
  • 111 Powers WJ, Rabinstein AA, Ackerson T. , et al; American Heart Association Stroke Council. 2018 guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2018; 49 (03) e46-e110
    CrossrefPubMedGoogle Scholar
  • 112 Genentech. Prescribing information Activase. 2018 https://www.gene.com/download/pdf/activase_prescribing.pdf . Accessed October 1, 2018
    PubMed
  • 113 Fugate JE, Rabinstein AA. Absolute and relative contraindications to IV rt-PA for acute ischemic stroke. Neurohospitalist 2015; 5 (03) 110-121
    CrossrefPubMedGoogle Scholar
  • 114 Etgen T, Steinich I, Gsottschneider L. Thrombolysis for ischemic stroke in patients with brain tumors. J Stroke Cerebrovasc Dis 2014; 23 (02) 361-366
    CrossrefPubMedGoogle Scholar
  • 115 Grimm SA, DeAngelis LM. Intratumoral hemorrhage after thrombolysis in a patient with glioblastoma multiforme. Neurology 2007; 69 (09) 936
    CrossrefPubMedGoogle Scholar
  • 116 Dearborn JL, Urrutia VC, Zeiler SR. Stroke and Cancer- A Complicated Relationship. J Neurol Transl Neurosci 2014; 2 (01) 1039
    PubMedGoogle Scholar